XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(FY)Aug 31, 2024 | (Q6)Feb 29, 2024 | (FY)Aug 31, 2023 | (Q6)Feb 28, 2023 | (FY)Aug 31, 2022 | (Q6)Feb 28, 2022 | (FY)Aug 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 44.23%3.32B | 73.83%1.65B | 160.36%2.3B | 137.20%946.59M | 156.20%884.37M | 21.19%399.06M | --345.18M | -42.29%329.3M | -53.50%426.56M | 30.26%570.65M |
Operating income | 44.23%3.32B | 73.83%1.65B | 160.36%2.3B | 137.20%946.59M | 156.20%884.37M | 21.19%399.06M | 345.18M | -42.29%329.3M | -53.50%426.56M | 30.26%570.65M |
Cost of sales | -44.51%-2.2B | -84.53%-1.06B | -157.89%-1.52B | -101.17%-575.81M | -107.53%-590.83M | -23.09%-286.23M | ---284.7M | 21.28%-232.53M | 34.69%-353.34M | -19.21%-295.39M |
Operating expenses | -44.51%-2.2B | -84.53%-1.06B | -157.89%-1.52B | -101.17%-575.81M | -107.53%-590.83M | -23.09%-286.23M | -284.7M | 21.28%-232.53M | 34.69%-353.34M | -19.21%-295.39M |
Gross profit | 43.67%1.12B | 57.22%582.93M | 165.33%778.85M | 228.61%370.78M | 385.28%293.54M | 16.61%112.83M | 60.49M | -64.85%96.77M | -80.54%73.23M | 44.64%275.26M |
Selling expenses | -94.69%-70.53M | -195.02%-36.41M | -197.02%-36.23M | -108.52%-12.34M | -156.02%-12.2M | -78.25%-5.92M | ---4.76M | 59.05%-3.32M | 82.47%-4.11M | -21.25%-8.11M |
Administrative expenses | -7.26%-257.5M | -29.92%-130.05M | -80.74%-240.06M | -65.79%-100.1M | -35.15%-132.82M | 2.21%-60.38M | ---98.28M | -5.41%-61.74M | 24.27%-68.79M | -37.14%-58.58M |
Impairment and provision | ---- | ---- | ---- | ---- | ---- | ---- | ---1.09B | ---- | ---- | ---- |
-Other impairment is provision | ---- | ---- | ---- | ---- | ---- | ---- | ---1.09B | ---- | ---- | ---- |
Operating interest expense | -38.16%-86.39M | ---- | -127.36%-62.53M | ---- | -61.71%-27.5M | -113.80%-14.45M | ---17.01M | ---6.76M | ---8.33M | ---- |
Special items of operating profit | 298.67%22.19M | -1,191.97%-8.16M | 64.67%5.57M | -89.05%747K | -59.27%3.38M | 15.95%6.83M | --8.3M | -39.39%5.89M | -18.71%20.63M | 8.02%9.71M |
Operating profit | 63.09%726.74M | 57.59%408.32M | 258.20%445.6M | 565.82%259.09M | 110.95%124.4M | 26.22%38.91M | -1.14B | -85.88%30.83M | -95.61%12.63M | 49.11%218.29M |
Financing cost | ---- | -38.86%-35.6M | ---- | ---25.63M | ---- | ---- | ---- | ---- | ---- | ---7.4M |
Share of profits of associates | 1,145.92%11.55M | 1,502.63%9.61M | -307.38%-1.1M | -565.05%-685K | 99.02%-271K | -106.32%-103K | ---27.53M | 1,682.52%1.63M | -55.22%678K | -114.13%-103K |
Share of profit from joint venture company | 494.35%2.17M | 94.90%-191K | -144.93%-549K | -692.39%-3.75M | 101.19%1.22M | -113.89%-473K | ---103.07M | --3.41M | ---- | ---- |
Earning before tax | 66.79%740.45M | 66.85%382.14M | 254.17%443.94M | 497.40%229.03M | 109.89%125.35M | 6.89%38.34M | -1.27B | -82.99%35.87M | -95.18%13.31M | 43.28%210.79M |
Tax | -68.41%-184.29M | -70.77%-96.27M | -274.90%-109.43M | -648.20%-56.38M | -118.48%-29.19M | -11.68%-7.54M | --157.99M | -1,124.50%-6.75M | 73.67%-1.81M | 26.44%-551K |
After-tax profit from continuing operations | 66.26%556.16M | 65.57%285.86M | 247.87%334.51M | 460.51%172.65M | 108.67%96.16M | 5.78%30.8M | -1.11B | -86.15%29.12M | -95.73%11.5M | 43.63%210.24M |
After-tax profit from non-continuing business | ---- | ---- | ---- | ---- | ---- | ---- | ---222.63M | ---- | --368.14M | ---- |
Earning after tax | 66.26%556.16M | 65.57%285.86M | 247.87%334.51M | 460.51%172.65M | 107.22%96.16M | 5.78%30.8M | -1.33B | -86.15%29.12M | 40.89%379.64M | 43.63%210.24M |
Minority shareholders should account for profits from continuing business | ---- | ---- | ---- | ---- | ---- | ---- | --1.31M | ---- | ---1.34M | ---- |
Minority shareholders should account for non-continuing business profits | ---- | ---- | ---- | ---- | ---- | ---- | --1.32M | ---- | --2.19M | ---- |
Minority profit | -687.04%-19.79M | -750.43%-3.02M | -563.59%-2.52M | 268.73%464K | -114.44%-379K | -111.50%-275K | --2.63M | 34.68%2.39M | -81.30%844K | -32.65%1.78M |
Shareholders should account for profits from continuing business | ---- | ---- | ---- | ---- | ---- | ---- | ---1.11B | ---- | --12.84M | ---- |
Shareholders should account for profits from non-continuing business | ---- | ---- | ---- | ---- | ---- | ---- | ---223.94M | ---- | --365.95M | ---- |
Profit attributable to shareholders | 70.89%575.96M | 67.77%288.88M | 249.11%337.03M | 454.06%172.19M | 107.23%96.54M | 16.28%31.08M | -1.33B | -87.18%26.73M | 42.97%378.79M | 45.03%208.47M |
Basic earnings per share | 71.40%0.2751 | 69.51%0.139 | 250.44%0.1605 | 457.82%0.082 | 107.31%0.0458 | 17.60%0.0147 | -0.6269 | -87.77%0.0125 | 43.43%0.1856 | 45.79%0.1022 |
Diluted earnings per share | 69.66%0.2723 | 68.78%0.1384 | 251.97%0.1605 | 461.64%0.082 | 107.27%0.0456 | 16.80%0.0146 | -0.6269 | -87.73%0.0125 | 42.89%0.1849 | 45.36%0.1019 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
Auditor | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.